Therapeutic area

Skin and subcutaneous tissue disorders – page 27

844 clinical trials
268 recruiting
353 conditions
25 countries

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

844 clinical trials

Hepatocellular carcinoma+5

Not yet recruiting

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:BNT327
Sponsor:Dualitybio Inc.

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Rituximab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Registered drug

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Squamous cell carcinoma of skin

Not yet recruiting

A study of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma

Registered drugNo placebo

A study of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Contact Research Centre

Skin wound

Not yet recruiting

Safety, tolerability and efficacy of topical human fibroblasts in patients with chronic refractory wounds (two-part study)

InvestigationalNo placebo

Safety, tolerability and efficacy of topical human fibroblasts in patients with chronic refractory wounds (two-part study)

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:HUMAN FIBROBLASTS

Contact Research Centre

Dermatitis atopic

Not yet recruiting

Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

Investigational

Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

Investigational

Bulgaria

Participants:18–64 years
Sponsor:Pfizer Inc.

Contact Research Centre

Diabetic foot+1

Not yet recruiting

Comparing local gentamicin or vancomycin hydrochloride to a drug combination for patients with diabetic foot osteomyelitis

Registered drugNo placebo

Comparing local gentamicin or vancomycin hydrochloride to a drug combination for patients with diabetic foot osteomyelitis

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Amoxicillin
Sponsor:Pirkanmaan hyvinvointialue

Contact Research Centre

Erysipelas

Not yet recruiting

A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.

Registered drugNo placebo

A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Dalbavancin
Sponsor:Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

Contact Research Centre

Vitiligo

Not yet recruiting

A study to evaluate the effectiveness of oxygen and narrow-band UVB phototherapy for treating patients with diffuse vitiligo

Registered drugNo placebo

A study to evaluate the effectiveness of oxygen and narrow-band UVB phototherapy for treating patients with diffuse vitiligo

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Oxygen
Sponsor:Centre Hospitalier Universitaire De Nice

Contact Research Centre

Malignant melanoma stage IV+1

Not yet recruiting

A study of ipilimumab and nivolumab to observe immune system changes in patients with unresectable stage III or IV melanoma

Registered drugNo placebo

A study of ipilimumab and nivolumab to observe immune system changes in patients with unresectable stage III or IV melanoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Lichen planus

Not yet recruiting

A study of upadacitinib in adults with erosive mucosal lichen planus and lichen planopilaris.

Registered drug

A study of upadacitinib in adults with erosive mucosal lichen planus and lichen planopilaris.

Registered drug

France

Participants:18–64 years
Substances:Upadacitinib
Sponsor:Centre Hospitalier Universitaire De Nice

Contact Research Centre

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trials Nivolumab33 clinical trials Sodium Chloride22 clinical trials Deucravacitinib19 clinical trials Cemiplimab18 clinical trials Upadacitinib17 clinical trials Ipilimumab15 clinical trials Rituximab13 clinical trials Cyclophosphamide12 clinical trials

Skin and subcutaneous tissue disorders – page 27

Conditions in this area

Clinical trials in Skin and subcutaneous tissue disorders

844 clinical trials

Hepatocellular carcinoma+5

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

Systemic scleroderma

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Systemic scleroderma

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Neoplasm+2

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Squamous cell carcinoma of skin

A study of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma

Skin wound

Safety, tolerability and efficacy of topical human fibroblasts in patients with chronic refractory wounds (two-part study)

Dermatitis atopic

Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

Diabetic foot+1

Comparing local gentamicin or vancomycin hydrochloride to a drug combination for patients with diabetic foot osteomyelitis

Erysipelas

A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.

Vitiligo

A study to evaluate the effectiveness of oxygen and narrow-band UVB phototherapy for treating patients with diffuse vitiligo

Malignant melanoma stage IV+1

A study of ipilimumab and nivolumab to observe immune system changes in patients with unresectable stage III or IV melanoma

Lichen planus

A study of upadacitinib in adults with erosive mucosal lichen planus and lichen planopilaris.

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.